Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natu…
FAIL · Does not pass the screen
110.12 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 4 days ago
Screened 2026-10-01 · the tape above runs as of 07:26 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 110.12 against the desk's fair-value range, base estimate 135.50, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price110.12 USD
Fair value135.50
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown110.12+0.0% to today
2026-09-03Read Accumulation126.64-13.0% to today
2026-08-04Read Markup107.01+2.9% to today ✓
2026-07-02Read Markdown86.21+27.7% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Kymera Therapeutics, Inc. holds its Markdown at $110.12. The statistical read favours the sellers, held for 97 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 97 days
Price at the screen
$110.12
Valuation
N/A trailing · -21.60 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.97
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.72%
Below 33%
Interest-bearing debt is just 4.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
44.25%
Below 33%
Interest-bearing cash and securities are 44.2% of assets, above the one-third limit.
Fail
Receivables
20.48%
Below 49%
Money owed to the company is 20.5% of assets, under the 49% limit.
Pass
Revenue purity
97.98%
Below 5%
98.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Kymera Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 44% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 23.0% margin of safety to the base estimate.
Third-party analyst targets: 22 covering, consensus Strong Buy. The average target sits +23% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Protein degradation story still all promise
Picture a drug that tells the body to chew up the exact protein causing disease. That is the neat idea behind Kymera, yet the firm remains years from any product and still posts no profit.
Revenue is rising fast at 56 percent, the ethical screen is clean and analysts cluster around a $125 target that sits just above the current price. None of that moves the needle for us. Forward earnings sit at a negative 26 times, return on equity is minus 27 percent and the company has yet to clear late-stage trials.
Clinical biotech bets live or die on binary trial data and cash burn. Negative margins and an unknown moat leave little room for error if the science slips. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KYMR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$110.12-13.0%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (22 analysts) rates it strong buy, with a mean price target of $118.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 18.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (22 analysts) rates it strong buy, with a mean price target of $118.
2026-08-04Markup · changed$107.01+24.1%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 24.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (22 analysts) rates it strong buy, with a mean price target of $118.
2026-07-18Markdown$86.21+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (22 analysts) rates it strong buy, with a mean price target of $118.
2026-07-03Markdown$86.21+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$86.21Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
